

REVIEW ARTICLE

DISORDERS OF FLUIDS AND ELECTROLYTES

Julie R. Ingelfinger, M.D., *Editor*

Physiological Approach to Assessment of Acid–Base Disturbances

Kenrick Berend, M.D., Ph.D., Aiko P.J. de Vries, M.D., Ph.D.,
and Rijk O.B. Gans, M.D., Ph.D.

From the Department of Internal Medicine, St. Elisabeth Hospital, Willemstad, Curaçao (K.B.); and the Division of Nephrology, Department of Medicine, Leiden University Medical Center, and Leiden University, Leiden (A.P.J.V.), and the Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen (R.O.B.G.) — both in the Netherlands. Address reprint requests to Dr. Berend at the Department of Internal Medicine, St. Elisabeth Hospital, Breedestraat 193, Willemstad, Curaçao, or at kenber2@me.com.

N Engl J Med 2014;371:1434–45.

DOI: 10.1056/NEJMra1003327

Copyright © 2014 Massachusetts Medical Society.

INTERNAL ACID–BASE HOMEOSTASIS IS FUNDAMENTAL FOR MAINTAINING life. Accurate and timely interpretation of an acid–base disorder can be lifesaving, but the establishment of a correct diagnosis may be challenging.¹ The three major methods of quantifying acid–base disorders are the physiological approach, the base-excess approach, and the physicochemical approach (also called the Stewart method).² This article reviews a stepwise method for the physiological approach.

The physiological approach uses the carbonic acid–bicarbonate buffer system. Based on the isohydric principle, this system characterizes acids as hydrogen-ion donors and bases as hydrogen-ion acceptors. The carbonic acid–bicarbonate system is important in maintaining homeostatic control. In the physiological approach, a primary change in the partial pressure of carbon dioxide (P_{CO_2}) causes a secondary “adaptive” response in the bicarbonate concentration and vice versa; further changes in carbon dioxide or bicarbonate reflect additional changes in acid–base status. The four recognized primary acid–base disorders comprise two metabolic disorders (acidosis and alkalosis) and two respiratory disorders (acidosis and alkalosis).

The hydrogen-ion concentration is tightly regulated because changes in hydrogen ions alter virtually all protein and membrane functions.^{2–6} Since the concentration of hydrogen ions in plasma is normally very low (approximately 40 nmol per liter), the pH, which is the negative logarithm of the hydrogen-ion concentration, is generally used in clinical medicine to indicate acid–base status.^{3–5,7} The terms “acidemia” and “alkalemia” refer to states in which the blood pH is abnormally low (acidic) or abnormally high (alkaline). The process in which the hydrogen-ion concentration is increased is called acidosis, and the process in which the hydrogen-ion concentration is decreased is called alkalosis.^{3,4} The traditional determination of acid–base values is based on the Henderson–Hasselbalch equation (in which pK denotes the acid dissociation constant):

$$pH = pK + \log_{10} \left(\frac{\text{bicarbonate } [HCO_3^-]}{[0.03 \times \text{partial pressure of arterial carbon dioxide } (P_{aCO_2})]} \right),$$

where bicarbonate is in millimoles per liter and P_{aCO_2} is in millimeters of mercury.^{6,7} An acid–base disorder is called “respiratory” when it is caused by a primary abnormality in respiratory function (i.e., a change in the P_{aCO_2}) and “metabolic” when the primary change is attributed to a variation in the bicarbonate concentration.

HISTORY AND PHYSICAL EXAMINATION

The first step in assessment of an acid–base disorder is a careful clinical evaluation. Various signs and symptoms often provide clues regarding the underlying acid–base disorder; these include the patient’s vital signs (which may indicate shock or

sepsis), neurologic state (consciousness vs. unconsciousness), signs of infection (e.g., fever), pulmonary status (respiratory rate and presence or absence of Kussmaul respiration, cyanosis, and clubbing of the fingers), and gastrointestinal symptoms (vomiting and diarrhea). Certain underlying medical conditions such as pregnancy, diabetes, and heart, lung, liver, and kidney disease may also hint at the cause. The clinician should determine whether the patient has taken any medications that affect acid-base balance (e.g., laxatives, diuretics, topiramate, or metformin) and should consider signs of intoxication that may be associated with acid-base disturbances (e.g., acetone feter as a sign of diabetic ketoacidosis or isopropyl alcohol intoxication, and visual disturbance as a symptom of methanol intoxication).

DETERMINATION OF THE PRIMARY ACID-BASE DISORDER AND THE SECONDARY RESPONSE

The second step is to determine the primary acid-base disorder and the secondary response. The range of pH that is compatible with life is 7.35 to 7.45 (a hydrogen-ion concentration $[H^+]$ of 38 to 45 nmol per liter).³ For the purposes of this review, the reference value for pH is 7.40 ± 0.02 , for P_{aCO_2} , 38 ± 2 mm Hg, and for $[HCO_3^-]$, 24 ± 2 mmol per liter. The four major acid-base disturbances are defined as primary acid-base disorders (Table 1 and Fig. 1). Empirical observations suggest that the homeostatic response to acid-base disorders is predictable and can be calculated.⁹⁻¹⁸ In response to metabolic acid-base disturbances, changes in the respiratory rate develop quickly, and a new steady-state P_{aCO_2} is reached within hours. In cases of persistent respiratory abnormalities, metabolic compensation develops slowly, and 2 to 5 days are required for the plasma bicarbonate concentration to reach a new steady-state level. A respiratory change is called "acute" or "chronic" depending on whether a secondary change in the bicarbonate concentration meets certain criteria (Table 1). Mixed acid-base disorders are diagnosed when the secondary response differs from that which would be expected.^{13,18-23}

There are several caveats concerning compensatory changes. Blood gas values can always be explained by two or more coexisting acid-base disorders.¹² The current prediction equations that

Table 1. Primary Acid-Base Disturbances with a Secondary ("Compensatory") Response.*

Metabolic acidosis

pH < 7.38 and bicarbonate $[HCO_3^-]$ < 22 mmol per liter

Secondary (respiratory) response: $P_{aCO_2} = 1.5 \times [HCO_3^-] + 8 \pm 2$ mm Hg† or $[HCO_3^-] + 15$ mm Hg‡

Complete secondary adaptive response within 12–24 hr

Superimposed respiratory acidosis or alkalosis may be diagnosed if the calculated P_{aCO_2} is greater or less than predicted

Metabolic alkalosis

pH > 7.42 and $[HCO_3^-]$ > 26 mmol per liter

Secondary (respiratory) response: $P_{aCO_2} = 0.7 \times ([HCO_3^-] - 24) + 40 \pm 2$ mm Hg or $[HCO_3^-] + 15$ mm Hg† or $0.7 \times [HCO_3^-] + 20$ mm Hg‡

Complete secondary adaptive response within 24–36 hr

Superimposed respiratory acidosis or alkalosis may be diagnosed if the calculated P_{aCO_2} is greater or less than predicted

Respiratory acidosis

pH < 7.38 and P_{aCO_2} > 42 mm Hg

Secondary (metabolic) response

Acute: $[HCO_3^-]$ is increased by 1 mmol/liter for each P_{aCO_2} increase of 10 mm Hg above 40 mm Hg

Chronic: generally $[HCO_3^-]$ is increased by 4–5 mmol/liter for each P_{aCO_2} increase of 10 mm Hg above 40 mm Hg

Complete secondary adaptive response within 2–5 days

Superimposed metabolic alkalosis or acidosis may be diagnosed if the calculated $[HCO_3^-]$ is greater or less than predicted

Respiratory alkalosis

pH > 7.42 and P_{aCO_2} < 38 mm Hg

Secondary (metabolic) response

Acute: $[HCO_3^-]$ is decreased by 2 mmol/liter for each P_{aCO_2} decrease of 10 mm Hg below 40 mm Hg

Chronic: $[HCO_3^-]$ is decreased by 4–5 mmol/liter for each P_{aCO_2} decrease of 10 mm Hg below 40 mm Hg

Complete secondary adaptive response in 2–5 days

Superimposed metabolic alkalosis or acidosis may be diagnosed if the calculated $[HCO_3^-]$ is greater or less than predicted

* Reference values for arterial blood gases are the following: pH, 7.4 ± 0.02 , partial pressure of arterial carbon dioxide (P_{aCO_2}), 40 ± 2 mm Hg, and bicarbonate, 24 ± 2 mmol per liter. Reference values for venous blood gases are the following: pH, 7.36 to 7.38, P_{vCO_2} , 43 to 48 mm Hg, and bicarbonate, 25 to 26 mmol per liter. To convert the values for P_{CO_2} to kilopascals, divide by 7.5006.

† This formula is also known as the Winters formula.

‡ These calculations are easy to make at the bedside but are not reliable at all bicarbonate concentrations. Data are from Berend.⁸

§ The secondary respiratory response is difficult to predict in metabolic alkalosis.

are used to assess acid-base status are approximations based on nearly 40-year-old studies involving humans and dogs.¹ Experimental studies of severe chronic hypocapnia and hypercapnia in humans are not ethically feasible; thus, data are insufficient to construct confidence limits for




Figure 1. Assessment of Acidosis.

Reference values for the alveolar-arterial (A-a) oxygen tension difference are less than 10 mm Hg in young persons and less than 20 mm Hg in the elderly. Δ AG denotes delta anion gap, P_{aCO_2} partial pressure of arterial carbon dioxide (mm Hg), P_{aO_2} partial pressure of arterial oxygen (mm Hg), and RTA renal tubular acidosis. To convert the values for P_{aCO_2} , P_{aO_2} , and the alveolar-arterial difference to kilopascals, multiply by 0.1333.

severe chronic respiratory alkalosis and acidosis. It is generally accepted that compensatory processes may normalize the pH only in chronic respiratory alkalosis. In contrast with older data, data from a more recent study¹³ indicate that the pH in chronic respiratory acidosis may be normal and, in individual cases, higher than generally recognized (pH >7.40).^{13,17,24} Furthermore, the usual compensatory changes in the P_{aCO_2} may be limited in cases of severe hypoxemia. Instruments used for the measurement of blood gas and electrolytes may differ, affecting results.²⁵⁻²⁷ Indeed, studies involving the use of modern analyzers show pH reference values (7.40 to 7.44)²⁸⁻³⁰ and secondary responses that differ from those published in textbooks.^{12,21,31} Although these differences are small, a reappraisal of the prediction equations may be needed.

EVALUATION OF THE METABOLIC
COMPONENT OF AN ACID-BASE
DISORDER

The third step in an evaluation is to consider the metabolic component of the acid-base disorder.

METABOLIC ACIDOSIS

Calculation of the anion gap is useful in the initial evaluation of metabolic acidosis.³²⁻⁴⁵ The sum of the positive and negative ion charges in plasma are equal in vivo: $[Na^+] + [K^+] + [Ca^{2+}] + [Mg^{2+}] + [H^+] + \text{unmeasured cations} = [Cl^-] + [HCO_3^-] + [CO_3^{2-}] + [OH^-] + \text{albumin} + \text{phosphate} + \text{sulfate} + \text{lactate} + \text{unmeasured anions}$ (e.g., inorganic anions).³⁵⁻⁴⁴ Routine measurement of all the ions in plasma is generally unnecessary. A more practical approach takes advantage of the fact that most plasma ions are normally present at relatively low concentrations and that variations into the pathologic range are quantitatively small. The three ions with the highest plasma

concentrations and largest variations in concentration are used to calculate the excess of "unmeasured anions" in metabolic acidosis that constitutes the "anion gap," which is calculated as $[Na^+] - [Cl^-] - [HCO_3^-]$.

A true ion gap, however, does not exist in vivo, because the sum of the positive and negative ion charges in plasma must be equal. Wide reference ranges of 3.0 to 12.0 mmol per liter up to 8.5 to 15.0 mmol per liter in the anion gap have been reported,^{33-36,43} owing to differences in laboratory methods.^{23,45} Consequently, clinicians should know the reference range for their own laboratory.

High-Anion-Gap Metabolic Acidosis

There are many causes of high anion-gap metabolic acidosis (Table 2). A useful mnemonic for the most common causes is GOLD MARRK (glycols [ethylene and propylene], 5-oxoproline [pyroglutamic acid], L-lactate, D-lactate, methanol, aspirin, renal failure, rhabdomyolysis, and ketoacidosis).⁴⁶ The anion gap increases when the concentration of bicarbonate decreases relative to levels of sodium and chloride because of overproduction of acid (in ketoacidosis, lactic acidosis, and drug and alcohol-related intoxication), underexcretion of acid (in advanced renal failure), cell lysis (in massive rhabdomyolysis), or other circumstances (e.g., the use of penicillin-derived antibiotics).

Uses and Limitations of the Anion Gap

Lactic acidosis accounts for about half the cases of a high anion gap³³⁻⁴⁹ and is often due to shock or tissue hypoxia.^{44,47} However, the anion gap is a relatively insensitive reflection of lactic acidosis — roughly half the patients with serum lactate levels between 3.0 and 5.0 mmol per liter have an anion gap within the reference range.^{39,40} The anion gap, which has a sensitivity and specificity below 80% in identifying elevated lactate levels, cannot replace a measurement of the serum lactate level.^{39,40,47-50} Nevertheless, lactate levels are not routinely measured or always rapidly available, and a high anion gap can alert the physician that further evaluation is necessary.^{34,39,43} Unfortunately, a baseline value of the anion gap is generally not available for an individual patient. In addition, the anion gap should always be adjusted for the albumin concentration, because this

Table 2. The Anion Gap in Relation to Common Medical Conditions with Metabolic Acidosis.***High anion gap****Overproduction of acid****Ketoacidosis** (diabetic ketoacidosis, alcoholic ketoacidosis, starvation)**Lactic acidosis**

L-Lactic acidosis

Type A — hypoxic (septic shock, mesenteric ischemia, hypoxemia, hypovolemic shock, carbon monoxide poisoning, cyanide)

Type B — nonhypoxic (thiamine deficiency, seizure, medications [nonnucleoside reverse-transcriptase inhibitors, metformin, propofol, niacin, isoniazid, iron], intoxication [salicylate, ethylene glycol, propylene glycol, methanol, toluene ingestion (early), paraldehyde])

D-Lactic acidosis in the short-bowel syndrome

Underexcretion of acid (advanced **renal failure**)†Impaired **lactate clearance** in liver failure (also type B acidosis)Cell **lysis** (massive rhabdomyolysis)Use of **penicillin**-derived antibiotics**Pyroglutamic acid** (5-oxoproline)³²**Normal anion gap****Loss of bicarbonate**

Gastrointestinal conditions (diarrhea, ureteral diversions, biliary or pancreatic fistulas)

Renal conditions (type 2 [proximal] renal tubular acidosis, toluene ingestion [late in the process of toluene intoxication], conditions associated with medications [ifosfamide, tenofovir, topiramate, carbonic anhydrase inhibitors such as acetazolamide])^{3,41}**Decreased renal acid excretion**

Early uremic acidosis

Type 1 renal tubular acidosis (e.g., due to amphotericin, lithium, Sjögren's syndrome)³

Type 4 renal tubular acidosis (hypoadosteronism or pseudohypoadosteronism)

Other causes: fluid resuscitation with saline, hyperalimentation (lysine, histidine, or arginine hydrochloride), administration of hydrochloride, ammonium chloride, cholestyramine, hippuric acid, sulfuric acid

* An anion gap of more than 10 mmol per liter above the upper limit of the reference value is highly suggestive of organic acidosis. A minor increase in the anion gap is less helpful in diagnosing metabolic acidosis.

† Advanced renal failure is indicated by a glomerular filtration rate below 20 ml per minute.

weak acid may account for up to 75% of the anion gap.^{36,39,40} Without correction for hypoalbuminemia, the estimated anion gap does not reveal a clinically significant increase in anions (>5 mmol per liter) in more than 50% of cases. For every decrement of 1 g per deciliter in the serum albumin concentration, the calculated anion gap should be increased by approximately 2.3 to 2.5 mmol per liter.^{9,36,39,40} Nevertheless, the albumin-corrected anion gap is merely an approximation, since it does not account for ions such as magnesium, calcium, and phosphate ions.

The anion gap can help to establish the diagnosis of diabetic ketoacidosis. In patients with this condition, the anion gap can be used to

track the resolution of ketosis^{9,15,23,33} and diagnose a normal anion-gap acidosis if large volumes of isotonic saline are administered.⁵⁰

A high anion gap with a normal lactate level in a patient with alcoholism may be an important clue for the diagnosis of alcoholic ketoacidosis. This diagnosis may be missed because the test widely used to assess ketonuria (the nitroprusside test) reacts only with acetoacetate, not with β -hydroxybutyrate, the primary keto acid seen in alcoholic ketoacidosis. The pH may also be misleadingly normal or elevated because of concomitant metabolic alkalosis from vomiting or respiratory alkalosis from liver disease, pregnancy, high temperature, or sepsis.^{18,51-53}

The anion gap can also aid in the diagnosis of **D-lactic acidosis** in patients with the short-bowel syndrome, because the standard lactate level (L-lactate) remains **normal** while the anion gap increases.⁴⁹

A **low or negative anion gap** is observed when **hyperchloremia** is caused by high levels of cations, as seen in lithium toxicity, monoclonal IgG gammopathy, or disorders characterized by high levels of calcium or magnesium. A negative anion gap is caused by pseudohyperchloremia in bromide or iodide intoxication.^{33,36,54}

Normal Anion-Gap Acidosis

Chloride plays a **central role** in intracellular and extracellular acid-base regulation.⁵⁵ A normal anion-gap acidosis occurs when the **decrease in bicarbonate** ions corresponds with an **increase in chloride** ions to retain **electroneutrality**, which is also called hyperchloremic metabolic acidosis. This type of acidosis occurs from gastrointestinal loss of bicarbonate (e.g., because of diarrhea or ureteral diversion), from renal loss of bicarbonate that may occur in defective urinary acidification by the renal tubules (renal tubular acidosis), or in early renal failure when acid excretion is impaired.^{12,56,57} Hospital-acquired hyperchloremic acidosis is usually caused by the infusion of large volumes of normal saline (0.9%).⁵⁸⁻⁶⁷ Hyperchloremic acidosis should lead to **increased renal excretion of ammonium**, and measurement of urinary ammonium can therefore be used to **differentiate between renal and extrarenal causes of normal anion-gap acidosis**. However, since urinary ammonium is seldom measured, the urinary anion gap and urinary osmolal gap are often used as surrogate measures of excretion of urinary ammonium.^{9,67}

The urinary anion gap ($[\text{Na}^+] + [\text{K}^+] - [\text{Cl}^-]$) is usually negative in normal anion-gap acidosis, but it will become positive when excretion of urinary ammonium (NH_4^+) (as ammonium chloride $[\text{NH}_4\text{Cl}]$) is impaired, as in renal failure, distal renal tubular acidosis, or hypoaldosteronism.^{9,67} A negative urinary anion gap occurs in normal anion-gap acidosis because of diarrhea and proximal renal tubular acidosis, in which the distal acidification is intact.⁵⁶ The urinary anion gap becomes unreliable when polyuria is present, when the urine pH exceeds 6.5,⁶⁷ or when urinary ammonium is excreted with an anion other than chloride (e.g., keto acids, ace-

tylsalicylic acid, D-lactic acid, and large quantities of **penicillin**).⁹ Furthermore, the acidification of the urine requires adequate distal delivery of sodium; thus, the usefulness of the urinary anion gap is questionable when the urinary sodium level is less than 20 mmol per liter.¹² In such cases, the urinary osmolal gap is generally more reliable.

The urinary osmolal gap determines the difference between measured and calculated urinary osmolality. The urinary osmolality is calculated as follows:

$$(2 \times [\text{Na}^+] + 2 \times [\text{K}^+]) + (\text{blood urea nitrogen} \\ \text{[in milligrams per deciliter]} \div 2.8) + \\ (\text{glucose [in milligrams per deciliter]} \div 18)$$

or (in millimoles per liter):

$$(2 \times [\text{Na}^+] + 2 \times [\text{K}^+]) + (\text{blood urea nitrogen}) + (\text{glucose}).$$

In patients without diabetes, the glucose concentration is often omitted from this calculation. A urinary osmolal gap below 40 mmol per liter in normal anion-gap acidosis indicates impairment in excretion of urinary ammonium. The urinary osmolal gap usually reflects the level of ammonium, except in the presence of large quantities of a nondissociated acid, such as β -hydroxybutyric acid in ketoacidosis. The urinary osmolal gap, as compared with the urinary anion gap, has a better correlation with the urinary ammonium value.^{9,67}

METABOLIC ALKALOSIS

The normal kidney is highly efficient at excreting large amounts of bicarbonate and, accordingly, the generation of metabolic alkalosis (Fig. 2) requires both an increase in alkali and impairment in renal excretion of bicarbonate.⁶⁸⁻⁷¹ Loss of gastric fluid and the use of diuretics account for the majority of cases of metabolic alkalosis. By measuring chloride in urine, one can distinguish between chloride-responsive and chloride-resistant metabolic alkalosis. If the effective circulating volume is reduced, the kidneys avidly reabsorb filtered sodium, bicarbonate, and chloride, largely through activation of the renin-angiotensin-aldosterone system, thus reducing the concentration of urinary chloride.

A (spot sample) urinary chloride concentration of less than 25 mmol per liter suggests




Figure 2 Assessment of Alkalosis.

Reference values for the alveolar–arterial (A–a) oxygen tension difference are less than 10 mm Hg in young persons and less than 20 mm Hg in the elderly. $Paco_2$ denotes partial pressure of arterial carbon dioxide (mm Hg), and Pao_2 partial pressure of arterial oxygen (mm Hg). To convert the values for $Paco_2$, Pao_2 , and the alveolar–arterial difference to kilopascals, multiply by 0.1333.

chloride-responsive metabolic alkalosis. Administration of fluids with sodium chloride (usually with potassium chloride) restores effective arterial volume, replenishes potassium ions, or both with correction of metabolic alkalosis.

Metabolic alkalosis with a urinary chloride concentration of more than 40 mmol per liter is mainly caused by inappropriate renal excretion of sodium chloride, often reflecting mineralo-corticoid excess or severe hypokalemia (potassi-

um concentration <2 mmol per liter). The administration of sodium chloride does not correct this type of metabolic alkalosis, which, for that reason, is called “chloride-resistant.” Diuretic-induced metabolic alkalosis is an exception because the concentration of chloride in urine may increase initially, until the diuretic effect wanes, after which the concentration will decrease to a level below 25 mmol per liter.⁶⁸⁻⁷⁰ Other important causes of chloride-resistant metabolic alkalosis are the Bartter syndrome, the Gitelman syndrome, extreme hypercalcemia, and severe magnesium deficiency. In contrast to hyperaldosteronism, these causes are not associated with sodium retention (Fig. 2).

EVALUATION FOR THE PRESENCE
OF MIXED METABOLIC ACID-BASE
DISTURBANCES

The fourth step in the evaluation of acid-base disturbances is to consider the possibility of a mixed metabolic acid-base disturbance. In high anion-gap metabolic acidosis, the magnitude of the increase in the anion gap (the delta AG, or Δ AG) is related to the decrease in the bicarbonate ions ($\Delta[\text{HCO}_3^-]$). To diagnose a high anion-gap acidosis with concomitant metabolic alkalosis or normal anion-gap acidosis, the so-called delta-delta (Δ - Δ) may be used.^{70,71} The delta gap is the comparison between the increase (delta) in the anion gap above the upper reference value (e.g., 12 mmol per liter) and the change (delta) in the concentration of bicarbonate ions from the lower reference value of bicarbonate ions (e.g., 24 mmol per liter).⁹ In ketoacidosis, there is a 1:1 correlation between the increase in the anion gap and the decrease in the concentration of bicarbonate. In lactic acidosis, the decrease in the concentration of bicarbonate is 0.6 times the increase in the anion gap (e.g., if the anion gap increases by 10 mmol per liter, the concentration of bicarbonate should decrease by approximately 6.0 mmol per liter). This difference is probably due to the lower renal clearance of lactate as compared with keto-anions.⁷¹ Hydrogen buffering in cells and bone takes time to reach completion. Accordingly, the ratio may be close to 1:1 with “very acute” lactic acidosis (e.g., shortly after seizures or in persons who exercise to the point of exhaustion).⁷¹ If $\Delta\text{AG} - \Delta[\text{HCO}_3^-] = 0 \pm 5$

mmol per liter in a patient with ketoacidosis or if $0.6 \Delta\text{AG} - \Delta[\text{HCO}_3^-] = 0 \pm 5$ mmol per liter in a patient with lactic acidosis, simple anion-gap metabolic acidosis is present. A difference greater than 5 mmol per liter suggests a concomitant metabolic alkalosis, and if the difference is less than -5 mmol per liter, a concomitant normal anion-gap metabolic acidosis is diagnosed.

In certain cases, normal values for concentrations of bicarbonate, Paco_2 , and pH do not ensure the absence of an acid-base disturbance. An increase in the anion gap of more than 5 mmol per liter may then be the only clue to an underlying mixed acid-base disorder.^{9,71} Because the individual anion gap and concentration of bicarbonate before the acid-base disorder are usually not known, and the ranges of normal values for the anion gap and the concentration of bicarbonate are wide, the $\Delta\text{AG} - \Delta[\text{HCO}_3^-]$ remains an approximation.^{70,71}

CONSIDERATION OF THE SERUM
(OR PLASMA) OSMOLAL GAP

The fifth step in the evaluation of an acid-base disturbance is to note the serum osmolal gap in any patient with an unexplained high anion-gap acidosis, coma, or suspicion of ingestion of a (toxic) alcohol and in hospitalized patients with an increased risk of iatrogenic propylene glycol intoxication (e.g., because of high-dose lorazepam administration in sedated patients in an intensive care unit).⁷²⁻⁷⁶ Laboratory confirmation of toxic alcohol ingestion is generally not rapidly available, and physicians must infer such a diagnosis by considering disorders that may necessitate immediate treatment. The osmolal gap is the difference between measured serum osmolality and calculated serum osmolality. The serum osmolality is calculated as

$$2 \times ([\text{Na}^+] \text{ [in millimoles per liter]}) + \\ (\text{glucose [in milligrams per deciliter]}) \div \\ 18 + (\text{BUN [in milligrams per deciliter]}) \div 2.8.$$

If ethanol is involved, the result of this calculation would be added to the amount of ethanol (in milligrams per deciliter) divided by 3.7. An osmolal gap below 10 mOsm per kilogram is considered to be normal, but the normal range in the general population is large (-10 to 10 mOsm per

Table 3. Common Medical Conditions Characterized by Respiratory Acidosis and Alkalosis.*

Type of Acidosis	Common Medical Conditions
Respiratory acidosis	
Acute	
Normal alveolar–arterial O ₂ difference	Depression of the central respiratory center by cerebral disease (encephalitis or trauma) or drugs (narcotics, barbiturates, or benzodiazepines)
High alveolar–arterial O ₂ difference†	Airway obstruction related to acute exacerbations of asthma or pneumonia
Chronic	
Normal alveolar–arterial O ₂ difference	Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, Guillain–Barré syndrome, or muscular dystrophy), kyphoscoliosis
High alveolar–arterial O ₂ difference†	Chronic obstructive pulmonary disease
Respiratory alkalosis	
Acute	
Normal alveolar–arterial O ₂ difference	Pain, anxiety, fever, stroke, meningitis, trauma, severe anemia, salicylate toxicity
High alveolar–arterial O ₂ difference†	Pneumonia, pulmonary edema, pulmonary embolism, aspiration, congestive heart failure, sepsis
Chronic	
Normal alveolar–arterial O ₂ difference	Pregnancy, hyperthyroidism, hepatic failure
High alveolar–arterial O ₂ difference†	Pulmonary embolism in pregnancy, liver failure with aspiration pneumonia

* The alveolar–arterial O₂ difference increases with age. For every decade a person has lived, the alveolar–arterial difference is expected to increase by 2 mm Hg; alternatively, one can compensate for age using the following formula: (alveolar–arterial O₂ difference = $[\frac{\text{Age}}{4} + 4]$).

† Minor defects may result in a normal alveolar–arterial O₂ difference.

liter).^{73,74} In ethylene glycol and methanol intoxication, the osmolal gap will be high shortly after ingestion, but substantial amounts of acids will not be generated for several hours.^{72–76} Symptoms are considerably delayed by simultaneous ethanol ingestion because of competition for the enzyme alcohol dehydrogenase.^{74–76}

The use of the osmolal gap has some pitfalls. The wide normal range of the osmolal gap in the general population renders the test rather insensitive to small but potentially toxic concentrations of ethylene glycol and methanol.⁷⁴ In addition, the osmolal gap lacks specificity, given that it may also be moderately el-

evated in other clinical situations such as lactic acidosis, alcoholic ketoacidosis, and diabetic ketoacidosis.⁷⁴

EVALUATION OF THE RESPIRATORY COMPONENT OF AN ACID–BASE DISORDER

The respiratory component of an acid–base disorder can be determined by differentiating between acute and chronic respiratory acid–base disorders with the use of clinical information and calculations (Table 1) and the oxygenation level. Hypoxemia, a major cause of lactic acidosis, may induce respiratory alkalosis. Evaluation of the partial pressure of arterial oxygen (Pao₂) relative to ventilation, with the alveolar–arterial oxygen–tension difference (hereafter called the alveolar–arterial difference) taken into account, may distinguish pulmonary from extrapulmonary diseases. The difference in the partial oxygen pressures between the alveolar and arterial side of the alveolar–capillary membrane will be high if the patient has associated lung disease (Table 3).^{77,78} The Pao₂ in the alveolus is not equal to that in the pulmonary circulation because physiological hypoventilation occurs in various portions of the lung; therefore, the alveolar–arterial difference will be about 5 to 10 mm Hg in healthy young persons and 15 to 20 mm Hg in healthy elderly persons. The alveolar–arterial difference is calculated as

$$F_{IO_2} \times (\text{barometric pressure} - \text{water-vapor pressure}) - P_{aO_2} - (P_{aCO_2} \div \text{gas-exchange ratio}).$$

The fraction of inspired oxygen (F_{IO₂}) is 0.21 in ambient air, the barometric pressure is 760 mm Hg at sea level, and the water-vapor pressure is 47 mm Hg at 37°C. The gas-exchange ratio, which is approximately 0.8 at steady-state levels, varies according to the relative utilization of carbohydrate, protein, and fat. At sea level and a body temperature of 37°C, the alveolar–arterial difference can be estimated^{77,78} as

$$F_{IO_2} \times (760 - 47) - P_{aO_2} - (P_{aCO_2} \div 0.8)$$

or

$$150 - P_{aO_2} - 1.25 P_{aCO_2}.$$

INTERPRETATION OF ACID–BASE DISORDERS IN THE CLINICAL CONTEXT

The **final step** in evaluating acid–base disorders is to determine the **cause** of the identified processes. The evaluation of the laboratory data must fit with the clinical presentation of the patient (see box). The stepwise approach described here can be helpful in assessing acid–base disorders, but one should always check for other information to support the diagnosis, such as a

lactate gap in ethylene glycol intoxication⁷⁹ (see the Supplementary Appendix, available with the full text of this article at NEJM.org) or an oxygen-saturation gap in carbon monoxide, methemoglobinemia, or cyanide intoxication.⁸⁰

CONCLUSIONS

Currently, there is no ideal method of assessing acid–base disturbances. The two other widely practiced methods also have limitations. **The physicochemical (strong ion or Stewart^{22,57,81})**

Three Case Examples

Patient 1, a 22-year-old woman who had been injured in an accident, received 6 liters of isotonic saline, after which the level of sodium was 135 mmol per liter, potassium 3.8 mmol per liter, chloride 115 mmol per liter, and bicarbonate 18 mmol per liter. The arterial blood pH was 7.28, and the P_{aCO_2} was 39 mm Hg. The urinary sodium level was 65 mmol per liter, potassium 15 mmol per liter, and chloride 110 mmol per liter.

This patient had a low anion-gap metabolic acidosis (2 mmol per liter), but she also had respiratory acidosis, because the expected P_{aCO_2} is lower ($1.5 \times \text{bicarbonate} + 8 \pm 2$ mm Hg = 35 ± 2 mm Hg). If these findings are the result of chest-wall expansion problem such as rib fractures, the alveolar–arterial O_2 difference could be normal, assuming no underlying lung pathology. The majority of patients with a normal anion-gap metabolic acidosis have diarrhea and renal tubular acidosis. The high chloride content of saline normalizes the anion gap because of the concomitant decrease in the level of bicarbonate. The low anion gap is probably the result of a low albumin level because of bleeding and dilution. The urinary anion gap ($[Na^+] + [K^+] - [Cl^-]$) was negative (–30 mmol per liter) because of the use of saline. It would have been positive in a patient with renal tubular acidosis type 1 or 4.

Patient 2, a 50-year-old woman with a recent onset of hypertension, the level of sodium was 150 mmol per liter, potassium 2.2 mmol per liter, chloride 103 mmol per liter, and bicarbonate 32 mmol per liter. The arterial blood pH was 7.50, and the P_{aCO_2} was 43 mm Hg.

This patient was found to have an aldoste-

rone-secreting adrenal adenoma. In a patient with metabolic alkalosis and hypokalemia, the clinician should always rule out vomiting and the use of diuretics before considering a renin–aldosterone problem. Vomiting should lead to a chloride level below 10 mmol per liter in the urine, whereas an aldosterone-secreting tumor should lead to a urinary chloride level greater than 40 mmol per liter.⁶³ The expected P_{aCO_2} would be $40 + 0.7 \times \Delta \text{bicarbonate ions} = 40 + 0.7 \times (32 - 24) = 45.7$ mm Hg, which is only marginally higher than the value in the patient.

Patient 3, a previously healthy 22-year-old man, developed large volumes of watery diarrhea from infectious gastroenteritis. Laboratory tests revealed a plasma sodium concentration of 140 mmol per liter, potassium 3.0 mmol per liter, chloride 86 mmol per liter, and bicarbonate 38 mmol per liter. The arterial blood pH was 7.60, and the P_{aCO_2} was 40 mm Hg.

The patient had metabolic alkalosis. The levels of pH and bicarbonate increased, but because the P_{aCO_2} did not increase, the patient also had respiratory alkalosis, perhaps because of stress or fever. The albumin-uncorrected anion gap was 16 mmol per liter; a much higher value might be indicative of additional metabolic acidosis. Also, metabolic alkalosis, particularly that which is caused by vomiting or diuretic use, can be associated with an increment in the serum anion gap of approximately 4 to 6 mmol per liter because of an increase of the albumin concentration and its release of protons.³³ The metabolic alkalosis was the result of gastrointestinal losses.

approach is complex and often requires cumbersome calculations that cannot be performed at the bedside. Many clinicians think that it does not provide a diagnostic or prognostic advantage^{33,42,81} and that the large number of parameters used in calculations will increase the magnitude of variability and error.²⁶ The standard base-excess method accurately quantifies the change in metabolic acid-base status in vivo and is conveniently provided by the blood-gas ma-

chine.⁸² However, “mixed” acid-base disorders will not be detected⁴² by that method without the use of elaborate base-excess partitioning.^{34,52,53} Therefore, in our view, the physiological approach, considered here, remains the simplest, most rigorous, and most serviceable approach to the assessment of acid-base disorders.⁴²

No potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

- Narins RG, Emmett M. Simple and mixed acid-base disorders: a practical approach. *Medicine* (Baltimore) 1980;59:161-87.
- Morris CG, Low J. Metabolic acidosis in the critically ill: part 1. Classification and pathophysiology. *Anaesthesia* 2008;63:294-301.
- Rennke HG, Denker BM. Renal pathophysiology, the essentials. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2010.
- Guyton AC, Hall JE. Textbook of medical physiology. 11th ed. Philadelphia: Saunders Elsevier, 2006.
- Palmer BF. Approach to fluid and electrolyte disorders and acid-base problems. *Prim Care* 2008;35:195-213.
- Henderson LJ. The theory of neutrality regulation in the animal organism. *Am J Physiol* 1908;21:427-48.
- Hasselbalch KA. The calculation of blood pH via the partition of carbon dioxide in plasma and oxygen binding of the blood as a function of plasma pH. *Biochem Z* 1916;78:112-44.
- Berend K. Bedside rule secondary response in metabolic acid-base disorders is unreliable. *J Crit Care* 2013;28:1103.
- Reddy P, Mooradian AD. Clinical utility of anion gap in deciphering acid-base disorders. *Int J Clin Pract* 2009;63:1516-25.
- Ghosh AK. Diagnosing acid-base disorders. *J Assoc Physicians India* 2006;54:720-4.
- Rowe KJ, Arrowsmith JE. Interpretation of measurements of arterial blood gases. *Surgery* 2007;25:375-9.
- Finkel KW, Dubose TF. Metabolic acidosis. In: Dubose T Jr, Hamm L, eds. Acid base and electrolyte disorders: a companion to Brenner & Rector's The Kidney. Philadelphia: Saunders, 2002:55-66.
- Martini T, Menzies D, Dial S. Re-evaluation of acid-base prediction rules in patients with chronic respiratory acidosis. *Can Respir J* 2003;10:311-5.
- Kellum JA. Determinants of plasma acid-base balance. *Crit Care Clin* 2005;21:329-46.
- Jones BJ, Twomey PJ. The anion gap revisited. *Int J Clin Pract* 2009;63:1409-12.
- Dubin A, Meneses MM, Masevicius FD, et al. Comparison of three different methods of evaluation of metabolic acid-base disorders. *Crit Care Med* 2007;35:1264-70.
- Jones NL. Respiratory acidosis sans acidemia. *Can Respir J* 2003;10:301-3.
- Krapf R, Beeler I, Hertner D, Hulter HN. Chronic respiratory alkalosis — the effect of sustained hyperventilation on renal regulation of acid-base equilibrium. *N Engl J Med* 1991;324:1394-401.
- Ayers P, Warrington L. Diagnosis and treatment of simple acid-base disorders. *Nutr Clin Pract* 2008;23:122-7.
- Kellum JA, Murugan R. Anion gap and strong ion gap. In: Ronco C, Bellomo R, Kellum JA, eds. Critical care nephrology. Philadelphia: Elsevier, 2009:611-4.
- Berend K. Acid-base pathophysiology after 130 years: confusing, irrational and controversial. *J Nephrol* 2013;26:254-65.
- Fidkowski C, Helstrom J. Diagnosing metabolic acidosis in the critically ill: bridging the anion gap, Stewart, and base excess methods. *Can J Anaesth* 2009;56:247-56.
- Lolekha PH, Vanavanan S, Lolekha S. Update on value of the anion gap in clinical diagnosis and laboratory evaluation. *Clin Chim Acta* 2001;307:33-6.
- Ucgun I, Oztuna F, Dagli CE, Yildirim H, Bal C. Relationship of metabolic alkalosis, azotemia and morbidity in patients with chronic obstructive pulmonary disease and hypercapnia. *Respiration* 2008;76:270-4.
- Otani N, Ohde S, Mochizuki T, Ishimatsu S. Reliability of anion gap calculated from data obtained using a blood gas analyzer: is the probability of error predictable? *Am J Emerg Med* 2010;28:577-81.
- Nguyen BV, Vincent JL, Hamm JB, et al. The reproducibility of Stewart parameters for acid-base diagnosis using two central laboratory analyzers. *Anesth Analg* 2009;109:1517-23.
- Sarrazin F, Tessler MJ, Kardash K, McNamara E, Holcroft C. Blood gas measurements using the Bayer Rapid Point 405: are we basing our decisions on accurate data? *J Clin Monit Comput* 2007;21:253-6.
- Crapo RO, Jensen RL, Hegewald M, Tashkin DP. Arterial blood gas reference values for sea level and an altitude of 1,400 meters. *Am J Respir Crit Care Med* 1999;160:1525-31.
- Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B. Acid-base disturbances in critically ill patients with cirrhosis. *Liver Int* 2007;27:901-9.
- Zavorsky GS, Lands LC, Schneider W, Carli F. Comparison of fingertip to arterial blood samples at rest and during exercise. *Clin J Sport Med* 2005;15:263-70.
- Emmet M. Diagnosis of simple and mixed disorders. In: Dubose T Jr, Hamm L, eds. Acid base and electrolyte disorders: a companion to Brenner & Rector's The Kidney. Philadelphia: Saunders, 2002:41-53.
- Duewall JL, Fennes AZ, Richey DS, Tran LD, Emmett M. 5-Oxoprolin (pyroglutamic) acidosis associated with chronic acetaminophen use. *Proc (Bayl Univ Med Cent)* 2010;23:19-20.
- Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. *Clin J Am Soc Nephrol* 2007;2:162-74.
- Maciel AT, Park M. Differences in acid-base behavior between intensive care unit survivors and nonsurvivors using both a physicochemical and a standard base excess approach: a prospective, observational study. *J Crit Care* 2009;24:477-83.
- Feldman M, Soni N, Dickson B. Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. *J Lab Clin Med* 2005;146:317-20.
- Moe OW, Fuster D. Clinical acid-base pathophysiology: disorders of plasma anion gap. *Best Pract Res Clin Endocrinol Metab* 2003;17:559-74.
- Kellum JA. Making strong ion difference the “Euro” for bedside acid-base analysis. In: Vincent JL, ed. Yearbook of intensive care and emergency medicine. Berlin: Springer-Verlag, 2005:675-85.
- Hatherill M, Waggle J, Purves L, Reynolds L, Argent A. Correction of the anion gap for albumin in order to detect occult tissue anions in shock. *Arch Dis Child* 2002;87:526-9.
- Chawla LS, Shih S, Davison D, Junker C, Seneff MG. Anion gap, anion gap corrected for albumin, base deficit and unmeasured anions in critically ill patients: implications on the assessment of meta-

- bolic acidosis and the diagnosis of hyperlactatemia. *BMC Emerg Med* 2008;8:18.
40. Berkman M, Ufberg J, Nathanson LA, Shapiro NI. Anion gap as a screening tool for elevated lactate in patients with an increased risk of developing sepsis in the Emergency Department. *J Emerg Med* 2009;36:391-4.
 41. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. *Br J Clin Pharmacol* 2009;68:655-61.
 42. Adrogué HJ, Gennari FJ, Galla JH, Madias NE. Assessing acid-base disorders. *Kidney Int* 2009;76:1239-47.
 43. Farwell WR, Taylor EN. Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey. *CMAJ* 2010;182:137-41.
 44. Gunnerson KJ, Saul M, He S, Kellum JA. Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. *Crit Care* 2006;10:R22.
 45. Lolekha PH, Vanavan S, Teerakarnjana N, Chaichanajarennkul U. Reference ranges of electrolyte and anion gap on the Beckman E4A, Beckman Synchro CX5, Nova CRT, and Nova Stat Profile Ultra. *Clin Chim Acta* 2001;307:87-93.
 46. Mehta AN, Emmett JB, Emmett M. GOLD MARK: an anion gap mnemonic for the 21st century. *Lancet* 2008;372:892.
 47. Handy J. Lactate — the bad boy of metabolism, or simply misunderstood? *Curr Anaesth Crit Care* 2006;17:71-6.
 48. Lleverve XM. Lactate in the intensive care unit: pyromaniac, sentinel or fireman? *Crit Care* 2005;9:622-3.
 49. Chang YM, Chiew YW, Yang CS. The case mid R: a woman with severe metabolic acidosis. *Kidney Int* 2010;77:261-2.
 50. Noritomi DT, Soriano FG, Kellum JA, et al. Metabolic acidosis in patients with severe sepsis and septic shock: a longitudinal quantitative study. *Crit Care Med* 2009;37:2733-9.
 51. Hassan H, Joh JH, Bacon BR, Bastani B. Evaluation of serum anion gap in patients with liver cirrhosis of diverse etiologies. *Mt Sinai J Med* 2004;71:281-4.
 52. Funk GC, Doberer D, Osterreicher C, Peck-Radosavljevic M, Schmid M, Schnee-weiss B. Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis. *Liver Int* 2005;25:505-12.
 53. Ahya SN, José Soler M, Levitsky J, Battle D. Acid-base and potassium disorders in liver disease. *Semin Nephrol* 2006;26:466-70.
 54. Mansoor S, Siddiqui I, Adil S, Nabi Kakepoto G, Fatmi Z, Ghani F. Anion gap among patients of multiple myeloma and normal individuals. *Clin Biochem* 2007;40:226-9.
 55. Durward A, Skellett S, Mayer A, Taylor D, Tibby SM, Murdoch IA. The value of the chloride: sodium ratio in differentiating the aetiology of metabolic acidosis. *Intensive Care Med* 2001;27:828-35.
 56. Katzir Z, Dinour D, Reznik-Wolf H, Nissenkorn A, Holtzman E. Familial pure proximal renal tubular acidosis — a clinical and genetic study. *Nephrol Dial Transplant* 2008;23:1211-5.
 57. Corey HE, Vallo A, Rodríguez-Soriano J. An analysis of renal tubular acidosis by the Stewart method. *Pediatr Nephrol* 2006;21:206-11.
 58. Bull SV, Douglas IS, Foster M, Albert RK. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial. *Crit Care Med* 2007;35:41-6.
 59. Corey HE. The anion gap (AG): studies in the nephrotic syndrome and diabetic ketoacidosis (DKA). *J Lab Clin Med* 2006;147:121-5.
 60. Mrozik LT, Yung M. Hyperchloraemic metabolic acidosis slows recovery in children with diabetic ketoacidosis: a retrospective audit. *Aust Crit Care* 2009;22:172-7.
 61. Taylor D, Durward A, Tibby SM, et al. The influence of hyperchloraemia on acid base interpretation in diabetic ketoacidosis. *Intensive Care Med* 2006;32:295-301.
 62. Story DA, Morimatsu H, Bellomo R. Hyperchloraemic acidosis in the critically ill: one of the strong-ion acidoses? *Anesth Analg* 2006;103:144-8.
 63. Berend K, van Hulsteijn LH, Gans RO. Chloride: the queen of electrolytes? *Eur J Intern Med* 2012;23:203-11.
 64. Handy JM, Soni N. Physiological effects of hyperchloraemia and acidosis. *Br J Anaesth* 2008;101:141-50.
 65. Gennari FJ, Weise WJ. Acid-base disturbances in gastrointestinal disease. *Clin J Am Soc Nephrol* 2008;3:1861-8.
 66. Gattinoni L, Carlesso E, Maiocchi G, Polli F, Cadringer P. Dilutional acidosis: where do the protons come from? *Intensive Care Med* 2009;35:2033-43.
 67. Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. *J Am Soc Nephrol* 2002;13:2160-70.
 68. Laski ME, Sabatini S. Metabolic alkalosis, bedside and bench. *Semin Nephrol* 2006;26:404-21.
 69. Heffner AC, Murugan R, Madden N, Kellum JA. Diagnosis and therapy of metabolic alkalosis. In: Ronco C, Bellomo R, Kellum JA, eds. *Critical care nephrology*. Philadelphia: Elsevier, 2009:621-4.
 70. Adrogué HJ. Mixed acid-base disturbances. *J Nephrol* 2006;19:Suppl 9:S97-S103.
 71. Rastegar A. Use of the DeltaAG/DeltaHCO₃⁻ ratio in the diagnosis of mixed acid-base disorders. *J Am Soc Nephrol* 2007;18:2429-31.
 72. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. *Clin J Am Soc Nephrol* 2008;3:208-25.
 73. Whittington JE, La'ulu SL, Hunsaker JJ, Roberts WL. The osmolal gap: what has changed? *Clin Chem* 2010;56:1353-5.
 74. Lynd LD, Richardson KJ, Pursell RA, et al. An evaluation of the osmolal gap as a screening test for toxic alcohol poisoning. *BMC Emerg Med* 2008;8:5.
 75. Jammalamadaka D, Raissi S. Ethylene glycol, methanol and isopropyl alcohol intoxication. *Am J Med Sci* 2010;339:276-81.
 76. Horinek EL, Kiser TH, Fish DN, MacLaren R. Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions. *Ann Pharmacother* 2009;43:1964-71.
 77. Moammar MQ, Azam HM, Blamoun AI, et al. Alveolar-arterial oxygen gradient, pneumonia severity index and outcomes in patients hospitalized with community acquired pneumonia. *Clin Exp Pharmacol Physiol* 2008;35:1032-7.
 78. Jones JS, VanDeelen N, White L, Dougherty J. Alveolar-arterial oxygen gradients in elderly patients with suspected pulmonary embolism. *Ann Emerg Med* 1993;22:1177-81.
 79. Meng QH, Adeli K, Zello GA, Porter WH, Krahn J. Elevated lactate in ethylene glycol poisoning: true or false? *Clin Chim Acta* 2010;411:601-4.
 80. Mokhlesi B, Leiken JB, Murray P, Corbridge TC. Adult toxicology in critical care: part I: general approach to the intoxicated patient. *Chest* 2003;123:577-92.
 81. Kurtz I, Kraut J, Ornekian V, Nguyen MK. Acid-base analysis: a critique of the Stewart and bicarbonate-centered approaches. *Am J Physiol Renal Physiol* 2008;294:F1009-F1031.
 82. Tuhay G, Pein MC, Masevicius FD, Kutscherauer DO, Dubin A. Severe hyperlactatemia with normal base excess: a quantitative analysis using conventional and Stewart approaches. *Crit Care* 2008;12:R66.

Copyright © 2014 Massachusetts Medical Society.

IMAGES IN CLINICAL MEDICINE

The Journal welcomes consideration of new submissions for Images in Clinical Medicine. Instructions for authors and procedures for submissions can be found on the Journal's website at NEJM.org. At the discretion of the editor, images that are accepted for publication may appear in the print version of the Journal, the electronic version, or both.

Corroborative analyses are one possible solution.² We conducted a post hoc corroborative efficacy analysis that combined the primary and secondary end points. We found that the device was consistently associated with improved symptoms, function, and quality of life, as compared with a sham intervention.

Coronary-sinus reduction is a device-based therapy for improvement of symptoms in patients with severe angina who had exhausted conventional therapies. Therefore, the primary end point of the COSIRA trial aimed to answer the question of whether the device is an effective treatment to improve symptoms of angina.

Placebo treatment alone can result in substantial improvement in angina symptoms and in exercise duration. Our sham-controlled clinical trial was designed to eliminate both patient bias and investigator bias in the interpretation of outcome end points. Extensive efforts were made so that the patients and the physician performing the follow-up were unaware of the treatment assignment.

Implantation of the coronary-sinus reducing

device is a simple procedure, and there was not much difference in the length of the procedure between the sham group and the treatment group. Also, there was no difference in the post-procedural care between the two groups.

Shmuel Banai, M.D.

Tel Aviv Medical Center
Tel Aviv, Israel
banais@netvision.net.il

Stefan Verheye, M.D. Ph.D.

Antwerp Cardiovascular Center
Antwerp, Belgium

E. Marc Jolicœur, M.D.

Montreal Heart Institute
Montreal, QC, Canada

Since publication of their article, the authors report no further potential conflict of interest.

1. Jolicœur EM, Ohman EM, Temple R, et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: trial design, outcomes, and regulatory issues. *Am Heart J* 2008;155:435-44.

2. Hare JM, Bolli R, Cooke JP, et al. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). *Circulation* 2013;127:1630-5.

DOI: 10.1056/NEJMc1503672

Acid–Base Problems in Diabetic Ketoacidosis

TO THE EDITOR: In their review article, Kamel and Halperin (Feb. 5 issue)¹ discuss “delta-delta,” the increase in the plasma anion gap and the decrease in the plasma bicarbonate concentration, for detecting the presence of coexisting acid–base disorders. The ratio is predicated on the assumption that in simple acidosis with an increased anion gap, the gap will increase by the same amount that the bicarbonate decreases. However, many laboratories currently measure electrolytes with the use of ion-selective electrodes, and the range for the anion gap is usually given as approximately 3 to 11. For the bicarbonate level, the laboratory in which I work provides a reference range of 21 to 31. So what does one use as the baseline value for each measurement? We typically do not have samples obtained from patients just before the onset of the acid–base disorder, so how does one know what baseline to use in calculating how much deviation has occurred? For the anion gap, is it 3 or 11 or in between, and for the bicarbonate concentration, is it 21 or 31 or in between? This ambiguity leads

me to question the value of “delta-delta” in assessing acid–base problems.

Mark Joy, M.D., J.D.

VA Pittsburgh Healthcare System
Pittsburgh, PA
mark.joy@va.gov

No potential conflict of interest relevant to this letter was reported.

1. Kamel KS, Halperin ML. Acid–base problems in diabetic ketoacidosis. *N Engl J Med* 2015;372:546-54.

DOI: 10.1056/NEJMc1502745

TO THE EDITOR: Kamel and Halperin state that sodium bicarbonate infusion may be considered in some patients with diabetic ketoacidosis to avoid possible deterioration in the hemodynamic status. This debated issue is supported by some older experimental studies, which suggest that severe acidosis might be associated with decreased cardiac contractility,¹ but not by clinical studies. We assessed cardiac function in 10 patients with severe ketoacidosis on admission and during correction of acidosis and did not observe any alteration in the left ventricular shortening

fraction or impairment in the hemodynamic status, whereas 3 of these patients had extremely severe acidosis.² Moreover, in patients with severe diabetic ketoacidosis, bicarbonate therapy does not modify the time required for the blood pH or bicarbonate level to normalize³ or improve hemodynamics.⁴ Except in the case of associated threat of hyperkalemia, the rationale for using bicarbonate therapy in ketoacidosis seems weak.

Eric Maury, M.D., Ph.D.

Côme Bureau, M.D.

Georges Offenstadt, M.D.

Hôpital Saint-Antoine

Paris, France

eric.maury@sat.aphp.fr

No potential conflict of interest relevant to this letter was reported.

1. Wildenthal K, Mierzwia DS, Myers RW, Mitchell JH. Effects of acute lactic acidosis on left ventricular performance. *Am J Physiol* 1968;214:1352-9.

2. Maury E, Vassal T, Offenstadt G. Cardiac contractility during severe ketoacidosis. *N Engl J Med* 1999;341:1938.

3. Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. *Ann Intern Med* 1986;105:836-40.

4. Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis: a prospective, controlled clinical study. *Ann Intern Med* 1990;112:492-8.

DOI: 10.1056/NEJMc1502745

TO THE EDITOR: Kamel and Halperin focus on three fundamental issues related to acid-base disorders. To reduce the risk of cerebral edema and hypokalemia, the authors suggest the infusion of 0.9% saline and potassium chloride at a concentration of 30 to 40 mmol per liter. However, they do not discuss the potential risks of such an infusion, since the administration of potassium entirely as potassium chloride contributes to the risk of hyperchloremic metabolic acidosis. Therefore, a combination of potassium phosphate and potassium chloride may be more appropriate, as suggested by the 2014 clinical practice guidelines of the International Society for Pediatric and Adolescent Diabetes.¹

Giulio Frontino, M.D.

Andrea Rigamonti, M.D.

Riccardo Bonfanti, M.D.

San Raffaele Scientific Institute

Milan, Italy

frontino.giulio@hsr.it

No potential conflict of interest relevant to this letter was reported.

1. Wolfsdorf JJ, Allgrove J, Craig ME, et al. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. *Pediatr Diabetes* 2014; 15:Suppl 20:154-79.

DOI: 10.1056/NEJMc1502745

THE AUTHORS REPLY: We agree with the comment by Joy that there is a practical problem with the use of the ratio of the change in the anion gap to the change in the bicarbonate concentration, as reviewed recently.¹ In our article, we focused on a conceptual problem in the use of this delta-delta ratio in patients with diabetic ketoacidosis. Even if the ratio of the increase in the plasma anion gap and the decrease in the plasma bicarbonate concentration is 1:1, this ratio does not reveal that a component of the metabolic acidemia is due to an “indirect loss of sodium bicarbonate,” because it is based on “concentrations” and not “contents,” a factor that ignores changes in extracellular fluid volume.

We agree that the evidence for an effect of acidemia on cardiac contractility is from experimental studies in animals. However, we do not think that the study by Maury et al., which was published as a letter to the Editor in the *Journal*, provides the evidence to dismiss the notion that severe acidemia may decrease cardiac contractility and contribute to hemodynamic instability.² The study included seven patients with diabetic ketoacidosis and three patients with alcoholic ketoacidosis. The mean (±SD) arterial pH was 7.07±0.20, and only three patients had severe acidemia. In addition, the method that was used to assess cardiac contractility, left ventricular fractional shortening on echocardiography, has its limitations.

We do not think that there are sufficient clinical data to justify the conclusion by Maury et al. There is only one randomized, controlled trial that examined the effect of sodium bicarbonate administration on mean arterial blood pressure in patients with diabetic ketoacidosis.³ A well-designed clinical trial is needed to assess whether there is a benefit of sodium bicarbonate administration in a subset of adult patients with diabetic ketoacidosis and with outcome measurements as we proposed in our review article.

Frontino et al. raise the issue of replacing the potassium deficit by administering a combination of potassium phosphate and potassium chloride and suggest that the administration of only potassium chloride contributes to the development of hyperchloremic acidosis. Our comment about the administration of potassium chloride was made in the context of preventing a decrease in the effective plasma osmolality to decrease the risk of cerebral edema. In this regard, there is no difference between the use of potassium chloride

or an equimolar potassium phosphate. The potassium deficit in patients with diabetic ketoacidosis is usually large; the administration of an appreciable amount of phosphate may cause precipitation of ionized calcium and hypocalcemia.⁴

Kamel S. Kamel, M.D.

Mitchell L. Halperin, M.D.

St. Michael's Hospital

Toronto, ON, Canada

mitchell.halperin@utoronto.ca

Since publication of their article, the authors report no further potential conflict of interest.

1. Kraut JA, Nagami GT. The serum anion gap in the evaluation of acid-base disorders: what are its limitations and can its effectiveness be improved? *Clin J Am Soc Nephrol* 2013;8:2018-24.

2. Maury E, Vassal T, Offenstadt G. Cardiac contractility during severe ketoacidosis. *N Engl J Med* 1999;341:1938.

3. Chua HR, Schneider A, Bellomo R. Bicarbonate in diabetic ketoacidosis — a systematic review. *Ann Intensive Care* 2011;1:23.

4. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. *J Clin Endocrinol Metab* 1983;57:177-80.

DOI: 10.1056/NEJMc1502745

More on Sweet's Syndrome in Patients with MDS and MEFV Mutations

TO THE EDITOR: In their letter to the Editor, Jo et al. (Feb. 12 issue)¹ describe two Japanese patients with the myelodysplastic syndrome (MDS) and skin lesions consistent with Sweet's syndrome. Since the two patients had a history of periodic inflammatory flares, the authors investigated MEFV, the gene that is responsible for familial Mediterranean fever,^{2,3} a recessive autoinflammatory disorder. Sequence analyses of MEFV showed a single, probably benign sequence variant carried by each patient: R202Q, which should not be reported, according to recent guidelines for genetic diagnosis,⁴ and G304R, a variant of unknown clinical significance. The frequency of each mutation in Japan is 3 to 4%.⁵

The authors fairly admit that these heterozygous mutations were not sufficient to induce inflammatory symptoms. The symptoms were not alleviated by colchicine, a treatment that is effective in 95% of the patients with familial Mediterranean fever. Furthermore, familial Mediterranean fever is typically diagnosed in childhood, and these patients were both 63 years old. Altogether, the clinical, genetic, and epidemiologic data that were presented in this report argue strongly against a diagnosis of familial Mediterranean fever. Also, Sweet's syndrome was not confirmed on skin biopsy in Patient 1. We believe that the authors' suggestion to consider MEFV analysis in patients with MDS who have marked neutrophilia and fever or in those with Sweet's syndrome is premature or even misleading.

Isabelle Koné-Paut, M.D.

Université Paris-Sud

Paris, France

Véronique Hentgen, M.D.

Hôpital Versailles

Versailles, France

Isabelle Touitou, M.D., Ph.D.

Centre Hospitalier Régional Universitaire de Montpellier
Montpellier, France

isabelle.touitou@inserm.fr

for CeRéMAI, the French Reference Center
for Autoinflammatory Diseases

No potential conflict of interest relevant to this letter was reported.

1. Jo T, Horio K, Migita K. Sweet's syndrome in patients with MDS and MEFV mutations. *N Engl J Med* 2015;372:686-8.

2. French FMF Consortium. A candidate gene for familial Mediterranean fever. *Nat Genet* 1997;17:25-31.

3. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. *Cell* 1997;90:797-807.

4. Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. *Ann Rheum Dis* 2012;71:1599-605.

5. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 2001;29:308-11.

DOI: 10.1056/NEJMc1503146

TO THE EDITOR: In my opinion, the skin lesions of the two patients who are described by Jo et al. were insufficient to lead to the diagnosis of Sweet's syndrome. For such a diagnosis, two major criteria and at least two of four minor criteria